Clinical Trials Directory

Trials / Completed

CompletedNCT01668069

Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
36 (actual)
Sponsor
United States Naval Medical Center, San Diego · Federal
Sex
Female
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Our purpose is to determine whether ondansetron, a commonly used antiemetic, is equivalent in efficacy to the combination of pyridoxine and doxylamine, the currently recommended first line therapy for nausea and vomiting in pregnancy by the American Congress of Obstetricians and Gynecologists (ACOG). Since both treatments are safe in pregnancy, many physicians are using ondansetron as first line in practice. Despite this practice and the recommendations from ACOG, there is not data to suggest that ether practice is superior. This will be the first prospective, randomized, double blind, controlled trial comparing the two treatments. We hypothesize that ondansetron will be equally efficacious in reducing nausea and episodes of emesis. By alleviating nausea and vomiting associated with pregnancy, patients will likely benefit from less Emergency Department visits, urgent clinic visits, and admissions for progression to hyperemesis gravidarum.

Conditions

Interventions

TypeNameDescription
DRUGOndansetronOndansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.

Timeline

Start date
2012-10-01
Primary completion
2012-10-01
Completion
2013-04-01
First posted
2012-08-17
Last updated
2016-04-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01668069. Inclusion in this directory is not an endorsement.